HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain

•

0 gefällt mir•173 views

HCS Pharma is expanding its BIOMIMESYS® 3D cell culture product range with BIOMIMESYS® Brain, a system for culturing neuronal cells that reproduces the physiological conditions of the brain's extracellular matrix. BIOMIMESYS® technology facilitates 3D cell culture using a microenvironment based on hyaluronic acid and other components naturally present in tissues. BIOMIMESYS® Brain is available to assist with in vitro testing for the pharmaceutical and cosmetics industries to help reduce animal testing. HCS Pharma also offers developing cell culture protocols for specific cell types using its BIOMIMESYS® technology.

Gesundheit & Medizin

HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
BIOMIMESYS®
is a registered trademark
of HCS Pharma
+33 769 999 137
www.biomimesys.com
hello@biomimesys.com
HCS Pharma extends its 3D cell culture range BIOMIMESYS®
with BIOMIMESYS® Brain
Following the success of BIOMIMESYS® range of products, which accurately and
physiologically reproduces the microenvironment of liver, adipose and cancerous tissues,
HCS Pharma is expanding its product range with BIOMIMESYS® Brain, an exclusive and
innovative system for the 3D cell culture of neuronal cells.
BIOMIMESYS® technology, provided “ready-to-use”, is easy to handle for in vitro testing. It
reproduces physiological conditions thanks to a microenvironment based on Hyaluronic Acid, a product
naturally present in the extracellular matrix. BIOMIMESYS® Brain includes in particular collagen IV and
a cationic biopolymer that promotes the long-term culture of neural cells. In addition, its specific
Young's modulus makes its rigidity similar to that of the cerebral extracellular matrix.
All the features of BIOMIMESYS® Brain and the first validation tests are available on
https://biomimesys.com/products/biomimesys-brain/
Today, in vitro tests are a critical step in the development of new drugs for the pharmaceutical and
dermo-cosmetic industries. They make it possible to validate the efficacy of a molecule and test its
toxicity well before the costly phases of clinical testing. They also help to reduce or even replace the
use of animals in preclinical tests. However, these tests are still often performed with 2D cell culture
systems, which are not close enough to the human tissues to give predictive results. The transition to
3D cell culture tools is now necessary for research and industry. BIOMIMESYS® technology facilitates
this transition by reproducing the cellular microenvironment, as close as possible to biological reality.
Several other products are available:
• BIOMIMESYS® Liver : https://biomimesys.com/products/biomimesys-liver/
• BIOMIMESYS® Adipose Tissue : https://biomimesys.com/products/biomimesys-adipose-tissue/
• BIOMIMESYS® Oncology: https://biomimesys.com/products/biomimesys-oncology/
To assist its customers in the use of BIOMIMESYS® technology, HCS Pharma also proposes to develop
cell culture protocols in this environment for specific cell types, on request. BIOMIMESYS® technology
is protected by an exclusive patent held by HCS Pharma.
HCS Pharma
HCS Pharma is a biotechnology start-up located in Lille and Rennes, which offers research and
development services to companies in the pharmaceutical, dermo-cosmetic and food industries. Its
expertise: the development of new tests for in vitro pharmacology and their use in medium/high
throughput screening, using the innovative high throughput cellular imaging technology called High
Content Screening (HCS) and its new 3D culture technology BIOMIMESYS®.
Contact information
Nathalie MAUBON / CEO / nathalie.maubon@hcs-pharma.com / +33 (0)769 999 137

Weitere ähnliche Inhalte

Ähnlich wie HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain

Cryo Sheet 2017

e 7

Honing Haemostats

Team Consulting Ltd

Custom membrane protein antibody

Candy Swift

How to make in vitro models predictive of in vivo conditions? - By taking into account the 3D cellular organization of in vivo tissues - By including the cellular and matricial microenvironments with BIOMIMESYS® - By using OoC systems for dynamic in vivo-like in vitro systems Dynamic models hold promise for future predictive microphysiological systems (MPS). By combining BIOMIMESYS® as an ECM surrogate for 3D culture, and hiPSC-derived cells, these dynamic microfluidic systems will revolutionize the field, reproducing human tissues and predict human outcomes.

Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...

HCS Pharma

Immobilisation of GI.pdf

Dr Sumitha Jagadibabu

Biobanking 2010 Ta

tatisalla

BIOMIMESYS® range are hyaluronan based scaffolds developed to overcome the 2D flat culture limitations by recreating an in vivo physiology within the in vitro environment. BIOMIMESYS® Adipocyte scaffold is made of RGDS-grafted Hyaluronic acid (1.6 MDa), Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type VI) to mimic fat tissue-ECM composition.

BIOMIMESYS® Adipose tissue, a relevant in vitro adipocyte 3D model

HCS Pharma

B.tech. ii engineering chemistry Unit-4 A chemical aspect of biotechnology

Rai University

Sartorius is a well respected global solution provider within the biologics industry, especially for antibody and vaccine production. Our proven products and services are being diversified for upstream and downstream processing of cells and viruses for allogeneic and autologous advanced therapies. Sartorius provides the cellular immunotherapy industry with a range of scalable single-use production technologies. Our portfolio supports viral vector transduction, cell expansion, and downstream processing steps including harvest, wash, and concentration of cells

Sartorius Solutions for Cell & Gene based Therapies

Raymond Goyco, III

Hormone and Enzyme (Description and synthesis)

Ahmed Abdellatif

Materi Seminar Mikrobiologi Rapid microbiological methods

Guide_Consulting

The utilization of animal stem cells to grow muscle and fat tissues in vitro for consumption, dubbed “cell-based meat,” offers an unprecedented opportunity to transform animal agriculture and produce meat in a humane and sustainable way. This nascent, interdisciplinary industry intersects cell biology, tissue engineering, biochemical engineering, and food science, with tangential impacts on issues relating to environmental science, human health, and regulatory policies. This talk will provide an industry snapshot and highlight the current challenges to scaling cell-based meat production, focusing on the needs and opportunities for industrial biotechnology to participate in the development of new tools, resources, or optimizations required to reach price parity with traditional animal meat. Finally, applications for industrial biotechnology in the broader "cellular agriculture" fields will be discussed.

Biotech 2019 - Leveraging Advances in Industrial Biotechnology in the Cellula...

David Welch

kSep Systems

Bret Carr

biotechnology final.pptx

AliaTahir1

Advances in the Design of Bioreactor Systems.pdf

andreagalibayperez

Prospects of enzymes

Subhashis Dasgupta

automated methods.pptx

VaisHali822687

The BecA-ILRI Hub: Driving agricultural research using state of the art techn...

ILRI

Scope of Biotechnology by Rajesh sahu

rajesh sahu

Experience the perfect balance of health and refreshment with our probiotics and prebiotics drinks. Crafted with precision and care, our beverages offer a delicious way to support digestive wellness and promote a flourishing gut microbiome. Each sip delivers a symphony of beneficial bacteria and nourishing prebiotic fibers, fostering overall well-being and vitality, one refreshing drink at a time.

Probiotics and Prebiotics Drinks.pptx...

PMG Engineering Private Limited

Ähnlich wie HCS Pharma extends its 3D cell culture range BIOMIMESYS® with BIOMIMESYS® Brain (20)

Cryo Sheet 2017

Honing Haemostats

Custom membrane protein antibody

Poster - BIOMIMESYS® 3D hydroscaffold a matricial microenvironment for physio...

Immobilisation of GI.pdf

Biobanking 2010 Ta

BIOMIMESYS® Adipose tissue, a relevant in vitro adipocyte 3D model

B.tech. ii engineering chemistry Unit-4 A chemical aspect of biotechnology

Sartorius Solutions for Cell & Gene based Therapies

Hormone and Enzyme (Description and synthesis)

Materi Seminar Mikrobiologi Rapid microbiological methods

Biotech 2019 - Leveraging Advances in Industrial Biotechnology in the Cellula...

kSep Systems

biotechnology final.pptx

Advances in the Design of Bioreactor Systems.pdf

Prospects of enzymes

automated methods.pptx

The BecA-ILRI Hub: Driving agricultural research using state of the art techn...

Scope of Biotechnology by Rajesh sahu

Probiotics and Prebiotics Drinks.pptx...

Mehr von HCS Pharma

Poster HCSPHARMA (OncoLilleDays2022) - Mechanobiological characterization of ...

HCS Pharma

Abstract: Lung cancer is one of the most frequent cancers in the world with a high mortality rate. The discovery of oncogenic alterations in these cancers allowed the development of targeted therapies against several receptor tyrosine kinases (RTK) including EGFR, ALK or MET and contributed to improve the prognosis of some patients. Mutations impacting the MET receptor exon 14 splice sites (METex14) have recently been detected in about 3% of lung cancers and lead to the loss of the juxtamembrane domain with several negative regulatory sites. METex14 does not lead to constitutive activation of the receptor but we demonstrated that HGF, its ligand, is required for the full development of the transforming capabilities of the METex14 receptor in SCID-HGFhuman transgenic mice. Several clinical trials have shown that only half of METex14 patients responded to MET inhibitors. While encouraging, these results are lower than those obtained with other treatments such as EGFR inhibitors. Interestingly, METex14 mutations are frequently associated with other molecular alterations including PTEN loss or TP53 mutations. Furthermore, we have shown that many METex14 mutated patients have autocrine secretion of HGF ligand. Understanding how these co-alterations impact METex14 oncogenicity and sensitivity to existing therapies is of outmost importance to identify patients that could benefit from them.

Poster : Development of personalized therapeutic targeting in lung cancer wit...

HCS Pharma

In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and are linked to cancer initiation, progression, propagation, and drug resistances. BIOMIMESYS® is a Hyaluronic Acid-based matrix grafted with structural and adhesion molecules, which mimics the ECM/TECM. It is chemically defined and its composition and stiffness can be modified to reproduce the organ-specificity of the ECM, or to mimic a pathological microenvironment in vitro. We have demonstrated that the exposition of colon cancer cells cultured in BIOMIMESYS® Oncology matrix to an anti-proliferative drug showed a closer in vitro/in vivo correlation in the EC50 curve compared to 2D culture. Cancer cells can be advantageously grown in BIOMIMESYS® for several weeks in multiwell plates and in microfluidic chips for more advanced models. We also observed that modifications in the matrix composition and stiffness modify the cell behavior. Moreover, thanks to collaborations with academic laboratories, we demonstrated that BIOMIMESYS® allows to reproduce in vitro the behavior of cancerous cells in vivo, like mutation effects and metastasis propagation, and could be a relevant alternative to animal models. These results showed that the matricial microenvironment modifies the cell behavior in vitro and should be considered carefully in drug discovery. BIOMIMESYS® hydroscaffold™ is adapted to High Content Screening and represented a powerful tool to better select drug candidate.

Poster - Including the matricial tumoral microenvironment in 3D in vitro mode...

HCS Pharma

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. With a non-invasive approach, hiPSCs can be generated from urine samples of patients and HLCs have been used to model cholesterol metabolism regulation, by the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). This model provides promising advantages with a direct link to the patient and with an unlimited source of HLCs. But like all models, there are limitations, mainly by the neonatal characteristic of HLCs lead to difficulties for pharmacological investigations.   Therefore, to overcome these burdens, we chose to 1. Differentiate hiPSCs into HLCs in an innovative 3D <a href="https://hcs-pharma.com/biomimesys/">hyaluronic acid-based hydroscaffold</a>, BIOMIMESYS® produces by HCS Pharma to enhance their maturation. 2. Adapt our 3D differentiation process to a 96-well format to make it compatible for drug screening. 3. Characterization of the 3D HLCs model by metabolism tests and compare to primary human hepatocyte (PHH).   We gathered 3’ SRP data all along the differentiation process and RNAseq has been performed by comparing 2D and 3D differentiation conditions to characterize hiPSCs differentiation into liver organoids. We observed an enhanced expression of most hepatic genes and genes expressed by non-parenchymal cells such as stellate cells. Immunofluorescence data confirmed the co-localization of albumin-positive hepatocytes, desmin-positive stellate cells and LYVE1-positive endothelial cells in liver organoids. Finally, at a functional level, several CYP activities including CYP3A4 were detected at the basal level and successfully induced. Liver organoids responded to pharmacological treatments as shown by their ability to accumulate lipids upon amiodarone treatment or uptake LDL-bodipy upon statin treatment.   Altogether, our development gave rise to functional liver organoids generated with a unique and common procedure, in a process of automating for future high throughput screening.

HCS PHARMA - (ECM 2022) Development of innovative hiPSC-based model including...

HCS Pharma

Aim: About 90% of drug-candidates failed in clinical trials, in particular in neurology, due to a lack of efficacy. That highlights a lack of relevance in preclinical models, including in vitro models, which do not take into account the microenvironment, composed by glial cells and the Extracellular Matrix (ECM). The objective was to study the influence of the microenvironment in cerebral in vitro models, in the frame of Parkinson’s Disease (PD). Methods: First, we analyzed the influence of astrocytes on Luhmes cell sensitivity, a dopaminergic neuronal cell line, in 2D culture. Then, we developed a hyaluronic acid-based hydroscaffold for 3D cell culture, which mimics the ECM, and study the sensitivity of Luhmes cells in this model. Thirdly, we performed a co-culture of Luhmes cells and astrocytes in this matrix, to form a complex model including both the glial and the matricial microenvironments. Results: We observed a protective effect of astrocytes in 2D culture. In the hydroscaffold, Luhmes cells displayed a lower sensitivity compared to 2D culture, that was explained by a partial retention of toxic molecules in the matrix, and differences in neuronal protein expression. In the co-culture, we observed spheroids containing both neurons and astrocytes. Conclusions: This work highlighted that the microenvironment of neurons can modify the neuronal response in vitro, and should thus be considered carefully in academic research and in drug discovery. This model can be now used to study the microenvironment modifications in pathological conditions, and to develop innovative drugs targeting the microenvironment.

HCSPHARMA Importance of microenvironment in cerebral in vitro models for phen...

HCS Pharma

metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations.

Poster - A single procedure to generate functional hiPSCs-derived liver organ...

HCS Pharma

There is a 90% failure in clinical trials, due to efficacy and safety issues, which frequently concerns the central nervous system. That points a lack of relevance of preclinical models used upstream. In this frame, the aim of this study was to develop more relevant cerebral in vitro models, by including the matricial and cellular microenvironments, for drug discovery in Parkinson's disease. HD available on https://hcs-pharma.com/poster---importance-of-matricial-and-cellular-microenvironments-in-in-vitro-models-for-drug-discovery-in-parkinsons-disease/

Importance of matricial and cellular microenvironments in in vitro models for...

HCS Pharma

BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment. BIOMIMESYS®Liver hydroscaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver ECM composition.

BIOMIMESYS®Liver, a 3D cell culture model for maintaining and promoting hepat...

HCS Pharma

Abstract : a single procedure to generate functional hi ps cs-derived liver o...

HCS Pharma

Poster – Development and automation of 3D innovative hiPSC-based liver organo...

HCS Pharma

Poster – Development and automation of 3D innovative hiPSC-based liver organo...

HCS Pharma

Development of a new liver-on-chip including BIOMIMESYS® technology for mimic...

HCS Pharma

HCS Pharma complète sa gamme de culture cellulaire en 3D BIOMIMESYS® avec BIO...

HCS Pharma

We previously showed that human pluripotent stem cells (hiPSCs) provide a suitable model to study metabolic diseases upon hepatocyte-like cell (HLC) differentiation. In particular, HLCs have been used to model cholesterol metabolism regulation, by mimicking the main disease features in vitro. Human iPSCs can be generated from urine samples of patients with a well-described phenotype and carrying specific genotypes. This non-invasive approach allowed the study of LDLR- and PCSK9-mediated autosomal dominant hypercholesterolemia (ADH) as well as PCSK9-mediated familial hypobetalipoproteinemia (FHBL). While the direct link between hiPSCs and patients, as well as the abundance of HLCs provide promising advantages of such strategy, it is impaired mainly by the neonatal characteristic of HLCs as well as the difficulty to perform high throughput studies for pharmacological investigations. Therefore, to overcome these burdens, we choose to 1. Differentiate hiPSCs into HLCs in a 3D environment instead of the classical 2D culture systems to enhance their maturation; 2. Adapt our 3D differentiation process to a 96 wells format to make it compatible for drug screening. To reach our goals, we established a partnership with HCS Pharma, which has an expertise in high content phenotypic screening and produces an innovative 3D scaffold, BiomimesysTM. This scaffold is composed of hyaluronic acid that can be functionalized with extra cellular matric derivatives, with adjustable stiffness and porosity. We setup conditions for hiPSCs seeding and differentiation to reach a new protocol adapted to a 3D environment. Our preliminary data indicate that our procedure enhanced expression of hepatic markers such as transcription factors (FOXA2, FOXA3, HNF1a, HNF1b, HNF4a), cytochrome P450 (CYP450) family members (CYP3A4, CYP2A6, CYP7A1) or cholesterol metabolism regulators (PCSK9, Lipoprotein(a)). During our presentation, we will discuss our data hiPSCs differentiation in 3D, CYP450 activities and induction, as well as their application for the study of metabolic diseases.

3D innovative hiPSC-based models including the microenvironment for phenotyp...

HCS Pharma

As shown by AstraZeneca in Nature reviews*, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs. Therefore, relevant in vitro human model is needed to detect early neurotoxicity of drug candidates. In this study, sensitivity of iPSC-derived neuronal cells to 32 compounds is compared to the sensitivity of SH-SY5Y cells. Two types of iPS-derived cells are tested: central nervous system cells (CNS.4U™ cells) and peripheral nervous system cells (PERI.4U™ cells) from Ncardia. Toxic effects are then measured by HCS cell imaging.

Neurotoxicity assessment: Comparison between SH-SY5Y and iPSC-derived cells

HCS Pharma

BIOMIMESYS® range are hyaluronan based hydroscaffold developed to overcome the 2D flat culture limitations by recreating an in vivo-like physiology within the in vitro environment. BIOMIMESYS®Liver scaffold is made of RGDS and galactosamine-grafted Hyaluronic acid, Adipic acid dihydrazide crosslinker and extracellular matrix (ECM) proteins (collagen type I and collagen type IV) to mimic liver-ECM composition.

BIOMIMESYS® Liver, a 3D cell culture model for maintaining and promoting hep...

HCS Pharma

HCS for brain disorders / HCS Pharma at B4B mars 2018

HCS Pharma

La société HCS Pharma, spécialiste de l’imagerie cellulaire à haut débit et du développement de nouveaux modèles cellulaires, est née à Rennes (35) en août 2014. Le 6 octobre dernier, elle a inauguré de nouvelles installations à Lille (59), au cœur du parc Eurasanté, et y a mis à l’honneur notamment sa toute nouvelle plate-forme robotique baptisée HAPIx, HCS Automation Platform for Imaging. Nathalie MAUBON, Présidente de l’entreprise, nous présente HCS Pharma et ses nouvelles ambitions portées par cette implantation lilloise, au plus proche des chercheurs et cliniciens en santé humaine...

Présentation de HCS Pharma dans la gazette du laboratoire - 2017

HCS Pharma

Human induced pluripotent stem cells (hiPSC) are becoming a relevant model for the study of liver metabolic diseases once differentiated into hepatocyte-like cells (HLC), and it has been shown that they can faithfully recapitulate autosomal dominant hypercholesterolemia (ADH). PCSK9 is a critical modulator of cholesterol homeostasis, and quickly became a hot target for ADH pharmacological treatment strategies. However, current cellular models to further decipher the role of PCSK9 in ADH are limited, especially to study the PCSK9 gain of function mutation S127R, which seems to interfere with LDL cholesterol homeostasis intracellularly by still unknown mechanisms.

Urine sample-derived human induced pluripotent stem cells as a model to study...

HCS Pharma

It was a real pleasure to be in the « High-Content and Phenotypic Screening » meeting in Cambridge. We were invited by our partner Molecular Devices to give a talk during the "User meeting Molecular Devices" about our vision of 3D culture in phenotypic screening and the impact of new technologies. We also presented a poster about "Neurotoxicity assay on 2D and 3D culture using High Content Screening technology".

3D culture in phenotypic screening : advantages, process changes and new tech...

HCS Pharma

Mehr von HCS Pharma (20)